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Abstract
Background: Acute postoperative pain is an integral risk factor in the development of chronic pain after breast
cancer surgery (BCS). Pectoral nerve block (PECSB) has been recently reported as an analgesic method for BCS.
Here, we retrospectively compared intraoperative opioid requirement, postoperative pain after BCS, and incidence
of postoperative nausea and vomiting (PONV) in patients who underwent BCS under total intravenous anesthesia
(TIVA) with or without PECSB.
Findings: We reviewed anesthesia charts and medical records of 146 patients who underwent BCS at Niigata
University Medical and Dental Hospital from January 2013 to March 2014; 36 patients were included in the TIVA
group, and 35 patients were included in the TIVA + PECSB group. Intraoperative remifentanil requirements were
significantly lower in the TIVA + PECSB group than in the TIVA group, and the cumulative distribution of remifentanil
was reduced in patients who received PECSB (TIVA: 10.9 ± 2.9 μg/kg/h; TIVA + PECSB: 7.3 ± 3.3 μg/kg/h; p < 0.001).
Postoperative pain scores during the 48 h after surgery were significantly lower in the TIVA + PECSB group than in the
TIVA group (TIVA: 2 [1–5]; TIVA + PECSB: 1 [0–5]; p = 0.03). However, administration of fentanyl during operation,
percentage of patients requiring supplemental analgesics, and incidence of PONV were not significantly different
between groups.
Conclusions: PECSB significantly reduced intraoperative remifentanil usage and postoperative pain. However, the
requirement for postoperative supplemental analgesics and the incidence of PONV did not differ. These data
suggested that PECSB may be useful for perioperative pain management in patients undergoing BCS.
Findings
Introduction
Breast cancer is the most common cancer among women,
and the incidence of breast cancer continues to rise. Acute
postoperative pain is an integral risk factor in the develop-
ment of chronic pain after breast cancer surgery (BCS);
40 % of women will have severe acute postoperative pain
after BCS [1, 2], potentially disrupting the quality of post-
operative recovery.
Thoracic paravertebral block (TPVB) is widely used for
anesthesia and postoperative pain management for BCS
[3–5]. However, TPVB is generally performed before gen-
eral anesthesia for surgery, and not all anesthesiologists feel
comfortable using such invasive techniques for BCS. Re-
cently, Blanco et al. reported the use of pectoral nerve
block (PECSB) as a new technique during BCS [6, 7].
PECSB is an interfascial plane block where local anesthetic
is deposited into the plane between the pectoralis major
muscle and the pectoralis minor muscle (PECS-I block)
and above the serratus anterior muscle at the third rib
(PECS-II block); blocking the pectoral; intercostobrachial;
intercostals III, IV, V, and VI; and long thoracic nerves by
PECSB is expected to provide analgesia for BCS [6, 7].
Moreover, PECSB is thought to be less invasive because it
can be performed with the patient in the supine position
and enables patients to undergo BCS after induction of
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general anesthesia. Interestingly, Bashandy and Abbas re-
cently reported that PECSB was able to reduce intraopera-
tive fentanyl requirement, postoperative pain, postoperative
morphine consumption, and postoperative nausea and
vomiting (PONV) in patients undergoing BCS [8].
In this study, we hypothesized that PECSB in patients
undergoing BCS may be beneficial for reduced intra-
and postoperative analgesics; we retrospectively analyzed
anesthesia charts and medical records of patients who
underwent BCS under total intravenous anesthesia
(TIVA) with or without PECSB.
Methods
Patients
This retrospective study was reviewed and approved
by the institutional review board of Niigata University
Medical and Dental Hospital (approved number: 1855
and trial registration number: UMIN000017875 [Effi-
cacy of pectoral nerve block for perioperative pain
management in breast cancer surgery], https://upload.
umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=
brows&recptno=R000020706&type=summary&language=E).
We reviewed the anesthesia charts and medical records of
all patients who underwent BCS under general anesthesia
at Niigata University Medical and Dental Hospital from
January 2013 to March 2014. During this period, we began
to introduce PECSB for BCS, and PECSB was carried out
if the anesthesiologists who were assigned to BCS were
capable of performing this technique and the patient con-
sented. Patients were excluded if they were male, under-
went reconstructive surgery, underwent bilateral surgery,
were a participant in an investigational new drug trial, re-
ceived another nerve block (such as TPVB or epidural
anesthesia), or underwent general anesthesia using inhaled
anesthetics. Patients with incomplete medical records
were also excluded from this study.
Analgesic methods and data collection
General anesthesia was induced and maintained with pro-
pofol and remifentanil. The dose of intraoperative propofol
was controlled by target-controlled infusion to maintain a
bispectral index (BIS) between 35 and 60. Intraoperative
remifentanil was adjusted to maintain adequate anesthetic
depth and systolic blood pressure (80–140 mmHg). Fen-
tanyl was used for supplemental intraoperative analgesia if
more than 0.5 μg/kg/min remifentanil was needed to main-
tain adequate anesthetic depth and systolic blood pressure
or for transitional postoperative analgesia as needed. After
induction of general anesthesia, PECS-I and PECS-II blocks
were performed as previously described with 0.25 or
0.375 % ropivacaine or 0.25 or 0.5 % levobupivacaine under
ultrasound visual guidance. We used 10–20 mL of local
anesthetic for PECS-I block and 20–40 mL of local
anesthetic for PESC-II block [6, 7]. Postoperative
supplemental analgesics were administered if the patients
felt more than mild postoperative pain (numerical rating
scale (NRS) ≥4). For patients who did not start oral intake,
a suppository of diclofenac sodium or intravenous flurbi-
profen axetil was chosen, whereas for patients who started
oral intake, loxoprofen sodium was chosen. Patient age,
height, weight, body mass index (BMI), target propofol
concentration for anesthesia maintenance, intraoperative
opioid (fentanyl and remifentanil) administration, max-
imal postoperative pain score with NRS (0–10 at 07:00,
12:00, and 18:00 or at the time the patient requested
supplemental analgesia during the first 48 h after surgery),
postoperative supplemental analgesic (diclofenac sodium,
flurbiprofen axetil, or loxoprofen sodium) administration,
and PONV incidence during the first 48 h after surgery
were extracted from the anesthesia charts and medical
records of each patient.
Data analyses
Data for continuous variables were presented as the
mean ± standard deviation (SD), and data for categorical
or ordinal variables, as well as data that did not obey the
normal distribution, were presented as the median and
range. Data for continuous variables and data that obeyed
the normal distribution were analyzed by paired t tests or
one-way analysis of variance (ANOVA). Data for categorical
variables or data that did not obey the normal distribution
were analyzed by Mann-Whitney U tests and Fisher’s exact
tests. The differences in distributions between patients
undergoing BCS with or without PECSB were analyzed by
Kolmogorov-Smirnov (K-S) tests. All statistical analyses
were performed using Microsoft Excel 2011 for Macintosh
(Microsoft, Redmond, WA) with a statistical macro
(XLSTAT2014; Addinsoft, New York, NY). All p values
were two-sided. Differences with p values of less than 0.05
were considered significant. The primary outcomes were
intraoperative opioid requirement and postoperative pain
during 48 h after BCS, and the secondary outcomes were
postoperative supplemental analgesic use and PONV inci-
dence during 48 h after BCS.
Results
During the study period, 146 patients underwent BCS. We
excluded patients with incomplete records (n = 27), those
who underwent bilateral surgery or simultaneously had
reconstructive surgery (n = 15), those who received another
block (TPBV or epidural anesthesia; n = 15) or inhaled
anesthesia (n = 17), and those participating in an investiga-
tional new drug trial (n = 1). In total, 36 patients were
included in the TIVA group, and 35 patients were included
in the TIVA+ PECSB group.
Demographic data (age and BMI), duration of anesthesia
and surgery, and target propofol concentration for main-
tenance were not different between the two groups
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(Table 1). Mean intraoperative remifentanil requirement
was significantly lower in the TIVA + PECSB group than
in the TIVA group, and cumulative distribution of remi-
fentanil requirement was shifted to the right in patients re-
ceiving PECSB (TIVA: 10.9 ± 2.9 μg/kg/h; TIVA +PECSB:
7.3 ± 3.3 μg/kg/h; p < 0.001 by Student’s t test and K-S test;
Fig. 1). However, intraoperative fentanyl administration was
not different between groups (TIVA: 0.84 [0–6.85] μg/kg/h;
TIVA+ PECSB: 0 [0–7.57] μg/kg/h; p = 0.11).
Maximal postoperative NRS during the 48 h after sur-
gery was significantly lower in the TIVA + PECSB group
than in the TIVA group, and the cumulative distribution
of NRS was shifted to the right in patients receiving
PECSB (TIVA: 2 [1–5]; TIVA + PECSB: 1 [0–5]; p = 0.03
by Mann-Whitney U test and p = 0.04 by K-S test; Fig. 2).
However, the percentage of patients who required sup-
plemental analgesics (diclofenac sodium, flurbiprofen
axetil, or loxoprofen sodium) was not different between
the two groups (TIVA: 24.3 % [9/36]; TIVA + PECSB:
17.1 % [6/35]; p = 0.32). Additionally, the incidence of
PONV was not different between the two groups (TIVA:
16.7 % [6/36]; TIVA + PECSB: 11.4 % [4/35]; p = 0.39).
Discussion
In this retrospective study, we showed that intraopera-
tive remifentanil administration and postoperative surgi-
cal pain during the 48 h after surgery in patients
undergoing BCS could be reduced by PECSB. These re-
sults suggested that PECSB was useful for suppression of
intraoperative nociception and reduction of postopera-
tive pain during the early period after surgery.
Compared to TPVB, PECSB is thought to be safer and
less invasive because PECSB is a type of superficial inter-
fascial plane block and can be performed under ultra-
sound guidance [6–8]. Consistent with a recent report
[8], total intraoperative opioid requirement and postop-
erative pain were reduced in the TIVA + PECSB group
compared with those in the TIVA group.
However, in contrast with another recent report, intraop-
erative fentanyl consumption, postoperative supplemental
analgesic requirement, and the incidence of PONV were
unchanged, regardless of PECSB. These discrepancies may
be explained by the following observations. We used fen-
tanyl as an analgesic for transitional analgesia in anticipa-
tion of pain relief during the early postoperative period;
therefore, similarities in fentanyl consumption may have
A B
Fig. 1 a Average dose of intraoperative remifentanil use in the TIVA and TIVA + PECSB groups. Data are shown as the means ± SDs. ***p < 0.001
by unpaired Student’s t tests. b Histogram and cumulative probabilities of intraoperative remifentanil dose in patients who underwent BCS with
TIVA or TIVA + PECSB. Red and blue bars denote the frequency of increases in intraoperative remifentanil doses (2 μg/kg/h) in the TIVA and TIVA +
PECSB groups, respectively. Red triangles and purple crosses denote the cumulative distribution of intraoperative remifentanil doses in the TIVA
and TIVA + PECSB groups, respectively
Table 1 Demographic data, duration of anesthesia and surgery,
and target propofol concentration for anesthesia maintenance
TIVA (n = 36) TIVA + PECSB
(n = 35)
p value
Age (years) 60.6 ± 10.9 56.0 ± 12.7 0.11
Body mass index (kg/m2) 23.8 ± 3.8 22.5 ± 2.8 0.11
Duration of anesthesia (min) 159 ± 47 165 ± 34 0.53
Duration of surgery (min) 108 ± 43 106 ± 35 0.81
Target propofol concentration
(μg/mL)
2.83 ± 0.46 2.95 ± 0.37 0.23
Data are shown as means ± SDs. Unpaired t tests were used to analyze the data
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affected the results. Additionally, there was insuffi-
cient statistical power for analyzing differences in fen-
tanyl consumption.
There was no inter-group difference in the inci-
dence of PONV in this study, even though the dose
of intraoperative remifentanil in the TIVA + PECSB
group was significantly lower than that in the TIVA
group. Some studies indicated that doses of both fentanyl
and remifentanil during surgery were risk factors for
PONV [9, 10], but other studies showed that intraopera-
tive remifentanil dose did not correlate with the severity
of PONV [11, 12]. This study suggests that intraoperative
dose of remifentanil may not affect the incidence of
PONV. However, the etiology of PONV is multifactorial,
and there are several risk factors other than perioperative
opioid use, homogenous gender group, shorter duration
of anesthesia, and avoidance of volatile anesthetics. There-
fore, the inhomogeneous background of the risk factors
of PONV in this study may influence the insignificant in-
cidence of PONV. Further extensive study is needed to
draw a solid conclusion about the correlation between the
lesser opioid consumption with PECS block and the inci-
dence and severity of PONV after breast surgery.
The lack of significant differences in the adminis-
tration of postoperative supplemental analgesics may
be explained by the following observations. PECSB
cannot block the anterior cutaneous branches of the
intercostal nerves, which innervate the nearby sternum;
therefore, the internal mammary region in the surgical site
may not be blocked by PECSB [13], although infusion
of remifentanil plus fentanyl would still be expected
to suppress intraoperative nociception. Moreover, pain
was treated on a case-by-case basis rather than using
a standard protocol.
Our study had several limitations. First, a variety of in-
traoperative analgesics were used for each patient. Sec-
ond, the concentration and volume of local anesthetics
for PECSB were not standardized among cases. Finally,
intraoperative antiemetic drug usage for prevention of
PONV was also not rigorously standardized; this may
have affected the observed incidence of PONV. Further
prospective, case-control studies are required in order to
overcome these limitations.
Conclusion
In this study, we evaluated the efficacy of PECSB for
BCS. PECSB significantly reduced intraoperative remi-
fentanil usage and postoperative pain. However, the re-
quirement for postoperative supplemental analgesics and
the incidence of PONV did not differ between the two
groups. Although a more in-depth analysis with a pro-
spective study design is needed, our analysis supported
that PECSB reduced postoperative pain to some extent
in patients undergoing BCS.
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Fig. 2 Histogram and cumulative probabilities of maximal postoperative pain during the 48 h after surgery in patients who underwent BCS with
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crosses denote cumulative distributions of NRS within the 48 h after surgery in the TIVA and TIVA + PECSB groups, respectively
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